|1.||Storb, Rainer: 40 articles (06/2013 - 03/2002)|
|2.||Sandmaier, Brenda M: 31 articles (09/2013 - 03/2002)|
|3.||Kontoyiannis, Dimitrios P: 29 articles (01/2015 - 04/2002)|
|4.||Kantarjian, Hagop: 27 articles (09/2015 - 01/2002)|
|5.||Giles, Francis J: 27 articles (09/2013 - 05/2002)|
|6.||Maloney, David G: 24 articles (06/2013 - 02/2002)|
|7.||Giralt, Sergio: 22 articles (12/2015 - 01/2002)|
|8.||Anderson, Kenneth C: 22 articles (06/2014 - 04/2002)|
|9.||Kantarjian, Hagop M: 21 articles (04/2015 - 01/2002)|
|10.||Huang, Xiao-Jun: 21 articles (08/2014 - 06/2004)|
|1.||Proteasome Endopeptidase Complex (Proteasome)IBA
03/01/2008 - "Proteasome inhibitors are proving to be of significant value in the treatment of hematologic malignancies and these observations may help to better understand the biology of therapy with these compounds."
03/01/2013 - "Proteasome inhibition has been recognized as a novel treatment modality in hematologic malignancies. "
04/01/2012 - "Proteasome inhibition is a novel treatment for several hematological malignancies. "
04/10/2014 - "Selective inhibitors for the human immunoproteasome LMP7 (β5i) subunit over the constitutive proteasome hold promise for the treatment of autoimmune and inflammatory diseases and hematologic malignancies. "
06/01/2015 - "Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies."
|2.||Granulocyte Colony-Stimulating Factor (G-CSF)IBA
08/01/2015 - "One hundred and five consecutive patients with hematologic malignancies who underwent G-CSF-primed peripheral blood haplo-HSCT without in vitro T-cell depletion in our single center were reported in this study. "
11/01/1999 - "This study retrospectively analyzed the effect of G-CSF dose on peripheral blood CD34+ cell collection from 91 patients with hematologic malignancies. "
10/01/2015 - "[Appropriate use of granulocyte-colony stimulating factor in treating hematologic malignancies]."
06/01/2014 - "[Appropriate use of granulocyte colony-stimulating factor in the management of hematologic malignancies]."
03/15/2012 - "Between 1996 and 1999, 172 patients (median age, 42 years) with hematologic malignancies were randomly assigned to receive either HLA-identical related bone marrow or G-CSF-mobilized peripheral blood mononuclear cells (G-PBMCs) after myeloablative conditioning. "
|3.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
08/01/2009 - "Preparative regimen containing Flud 40 mgxm(-2)xd(-1) on day -7 to -3 in place of cyclophosphamide (CTX) for haploidentical HSCT was given to 35 patients with hematologic malignancies (4 standard risk, 16 high risk, 15 relapse with no remission). "
03/01/1981 - "Continuous infusion of cyclophosphamide is a clinically effective method of ALL treatment and may have a role in the initial combination regimens for this hematologic malignancy."
04/01/2010 - "A retrospective analysis was performed of 185 patients with hematologic malignancies enrolled in 3 similar trials of NMA, related donor, haploidentical BMT incorporating high-dose posttransplantation cyclophosphamide for GVHD prophylaxis. "
06/01/2009 - "Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy."
08/01/2013 - "Transcript profiling and flow cytometry were used to explore cyclophosphamide-induced immunoadjuvanticity in patients with hematologic malignancies. "
01/01/2014 - "In 2003, oral fludarabine was introduced in the USA for the treatment of patients with hematologic malignancies as an alternative to its intravenous (i.v.) formulation; in 2008, it was introduced in México while the i.v. formulation was withdrawn. "
02/01/2012 - "A total of 335 patients with hematologic malignancies were given daily i.v. Bu 3.2 mg/kg × 4 and fludarabine 50 mg/m(2) × 5. Pharmacokinetic monitoring was conducted for both the test dose and first treatment dose of Bu (day -5). "
06/01/2010 - "Twenty patients with hematologic malignancies were given MSCs from third party unrelated donors 30-120 minutes before peripheral blood stem cells (PBSCs) from HLA-mismatched unrelated donors, after conditioning with 2 Gy total body irradiation (TBI) and fludarabine. "
01/01/2009 - "In 2003, oral fludarabine was introduced for the treatment of patients with hematologic malignancies as an alternative to its intravenous (i.v.) formulation. "
02/01/2008 - "We report Bu AUC and its association with clinical outcomes in 130 patients with hematologic malignancies given a once-daily i.v. Bu (3.2 mg/kg days -5 to -2) and fludarabine (Flu, 50 mg/m(2) days -6 to -2) regimen. "
05/01/2000 - "Several monoclonal antibodies, including Lym-1, have proven effective for treatment of hematologic malignancies. "
02/01/2015 - "The ecto-enzyme CD38 is gaining momentum as a novel therapeutic target for patients with hematological malignancies, with several anti-CD38 monoclonal antibodies in clinical trials with promising results. "
12/01/2008 - "In recent years, there has been a tremendous increase in the number of clinical studies with monoclonal antibodies and small molecules in the treatment of hematological malignancies. "
07/01/2003 - "Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan."
01/01/1983 - "In this study we have 1) recorded the prevalence of hematopoietic neoplasms (HN) in Mya arenaria within a 50 mile radius of Woods Hole, Massachusetts and 2) utilized cells from one HN bearing clam to generate a series of monoclonal antibodies. "
|6.||bortezomib (Velcade)FDA Link
01/01/2004 - "Available data suggest that bortezomib will be useful in the treatment of a variety of hematologic malignancies."
08/01/2014 - "Bortezomib, as a single or in combination therapy, demonstrates efficacy against MM or other hematological malignancies in clinical settings. "
01/15/2015 - "Furthermore, in light of success of Bortezomib in treating hematological malignancies, we describe the preclinical and clinical studies of therapeutic approaches targeting aberrant RING-finger E3s in HCC. "
09/01/2010 - "Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies."
02/01/2007 - "Phase II/III studies have supported the use of bortezomib in hematologic malignancies. "
|7.||Cytarabine (Cytosar-U)FDA LinkGeneric
11/01/2001 - "Sixteen children treated for hematological malignancies and in clinical remission were studied during treatment with six infusions of cytarabine given every 12 hr at a dose of 2 g/m(2). "
07/01/2012 - "Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies."
06/01/2006 - "In this study, we measured the concentration of cytarabine in saliva of nine patients with hematological malignancies who received high-dose cytarabine. "
12/01/1990 - "Phase II study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate), a derivative of cytosine arabinoside, on hematological malignancies was conducted by multi-institutional cooperative group. "
04/01/2015 - "Cytosine Arabinoside (Ara-C) is widely used to treat hematological malignancy in humans, but often becomes ineffective because of increased resistance to the drug which may lead to a worse prognosis. "
|8.||Etoposide (VP 16)FDA LinkGeneric
01/01/2001 - "Oral etoposide in patients with hematological malignancies: a clinical and pharmacokinetic study."
08/01/1984 - "[Phase II study of etoposide (NK 171) in advanced hematological malignancies]."
10/01/2004 - "We evaluated the efficacy and safety of a VP-16 (at less than the usual dose)/CY/TBI regimen for adults with hematological malignancies who are required to receive allo-BMT. "
12/01/1997 - "During the past 15 years, we have gained considerable experience with the combination of fractionated total-body irradiation (FTBI) and etoposide followed by allogeneic BMT for hematologic malignancies. "
09/01/1989 - "Promising response rates in this high risk group of hematologic malignancies warrant further evaluation of these etoposide containing conditioning regimens."
|9.||arsenic trioxide (Trisenox)FDA Link
03/01/2006 - "Arsenic trioxide (ATO), which acts through proapoptotic, antiproliferative, and antiangiogenesis mechanisms, has been used successfully to treat a variety of hematologic malignancies, including MDS. "
01/01/2005 - "Arsenic trioxide (ATO), which acts through pro-apoptotic, antiproliferative, and anti-angiogenesis mechanisms, has been used successfully to treat a variety of hematologic malignancies, including MDS. "
01/25/2015 - "Arsenic trioxide (ATO) is successfully used to treat hematological malignancies. "
04/01/2014 - "Efforts to enhance the antileukemic properties of arsenic trioxide are clinically relevant and may lead to the development of new therapeutic approaches for the management of certain hematological malignancies. "
07/01/2010 - "Combination therapy with arsenic trioxide for hematological malignancies."
08/01/2002 - "Intracellular antigens are of major importance for immunophenotyping of hematological malignancies, and flow cytometric detection of intracellular antigens was improved by the development of new permeabilization/fixation solutions. "
05/27/2015 - "MGD006 is a bispecific CD3xCD123 dual-affinity re-targeting (DART) molecule that binds T lymphocytes and cells expressing CD123, an antigen up-regulated in several hematological malignancies including AML. "
07/01/2014 - "Sixty-four consecutive patients with hematological malignancies in a single tertiary care institution underwent total body irradiation (TBI)-based myeloablative conditioning followed by six of six human leukocyte antigen (HLA)-identical sibling allogeneic SCT. "
03/01/2013 - "Patients aged ≤75 years with advanced hematologic malignancies with human leukocyte antigen-compatible donor were eligible. "
03/01/2011 - "A method to detect the antigen in the blood based on alterations in the erythrocyte sedimentation rate that occur when antiserum to ESA-10 is bound to the antigen in blood was devised and used here to determine the sensitivity and predictive value of the test in patients with biopsy proven non-hematologic malignancies, and in normal control subjects. "
|1.||Drug Therapy (Chemotherapy)
01/01/2013 - "Optimal chemotherapy with minimal toxicity is the main determinant of complete remission in patients with newly diagnosed hematological malignancies. "
12/01/2007 - "Home chemotherapy can be a feasible and potentially novel treatment option for some patients with hematologic malignancy, although the clinical course of the present patient suggested that patient selection is critical for the safe operation of home chemotherapy and that it is important to educate families on how to evaluate patients' conditions and how to cope with aggravation and admission arrangements in back-up hospitals."
10/01/2013 - "Despite the chemotherapy is successful in inducing remission of hematologic malignancy, this disease also has a high probability of relapse; besides, the toxicity of chemotherapy for these patients can not be avoided. "
08/01/2008 - "However, patients surviving for several years with essentially normal quality of life may be considered to be 'operationally cured.' Also, unlike with other hematologic malignancies relapsing after an autograft, recurrent disease can be treated with novel agents or repeat high-dose chemotherapy and autologous or allogeneic HSCT--and long-term survival is seen in a number of patients after relapse. "
10/01/2015 - "There is the potential to compromise efficacy when chemotherapy dosages are reduced, but the impact of dose adjustment on clinical response and toxicity in hematologic malignancies is unknown. "
05/01/2003 - "Hematopoietic stem cell transplants (HSCTs) are considered the best treatment option for many hematological malignancies, and transplant numbers have increased five-fold during the last decade. "
07/01/2005 - "Allogeneic transplant offers a curative option for selected hematological malignancies and improved disease free survival in those where cure is not possible. "
02/01/2010 - "We conclude that in patients who receive allo-HSCT as treatment for hematological malignancy and who are free of their original disease 2 years post transplant, mortality is low and the probability of durable remission is high. "
12/01/2009 - "However, a more sophisticated improvement in separating graft-versus-hematological malignancy effects from GVHD is required in the future."
03/15/2001 - "A TBI dose (fractionated) > 10 Gy may not necessarily be associated with a better outcome in patients undergoing allogeneic bone-marrow transplant for hematologic malignancies."
|3.||Hematopoietic Stem Cell Transplantation
04/01/2002 - "Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective treatment for selected hematological malignancies. "
02/01/2014 - "Allogeneic hematopoietic stem cell transplantation is a successful treatment for hematologic malignancies and a variety of genetic and metabolic disorders. "
03/01/2013 - "We will review the evidence that hematopoietic stem cell transplantation is well tolerated and effective in HIV-1-infected individuals with high-risk hematologic malignancies. "
08/01/2012 - "Patients with hematologic malignancies can be successfully treated with donor lymphocyte infusion after HLA-matched allogeneic hematopoietic stem cell transplantation. "
07/01/2006 - "Our data suggest that younger donor age is associated with better outcome after sub-myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for hematologic malignancies due to lower TRM and relapse. "
|4.||Transplantation (Transplant Recipients)
06/01/2015 - "Allogeneic blood and marrow transplantation (allo-BMT) is an effective immunotherapeutic treatment that can provide partial or complete remission for patients with hematological malignancies. "
11/01/2014 - "Double umbilical cord blood transplantation is increasingly applied in the treatment of adult patients with high-risk hematological malignancies and has been associated with improved engraftment as compared to that provided by single unit cord blood transplantation. "
12/01/2007 - "In contrast to other hematologic malignancies treated with high-dose therapy, autografted myeloma patients continue to relapse several years after transplantation, and few patients are cured with this modality. "
01/01/2003 - "High-dose myeloablative therapy with allogeneic hematopoietic transplantation is an effective treatment for hematologic malignancies, but this approach is associated with a high risk of complications. "
01/01/1997 - "High-dose chemoradiotherapy with transplantation of CD34+ PBSCs purified by the immunomagnetic bead method was thus shown to be an active and safe therapy for refractory hematological malignancies with bone marrow or peripheral blood involvement. "
|5.||Stem Cell Transplantation
02/01/2011 - "This study was aimed to investigate the curative efficacy of allogenetic hemopoietic stem cell transplantation (allo-HSCT) using FLAG and modified BUCY conditioning regimen for patients with refractory and relapse or high risk hematologic malignancies. "
01/01/2008 - "The therapeutic efficacy of donor lymphocyte infusions has been proven for patients with relapsed hematologic malignancies after allogeneic stem cell transplantation. "
10/01/2010 - "Stem cell transplantation (SCT) is a useful treatment for hematological malignancies, but it is limited to younger patients because of its high treatment-related mortality. "
03/11/2008 - "Patients with hematological malignancies can be successfully treated with HLA-matched T cell-depleted allogeneic stem cell transplantation (alloSCT) and subsequent donor lymphocyte infusions (DLIs). "
02/15/2014 - "Allogeneic hematopietic stem cell transplantation (aHSCT) is widely used for the treatment of hematologic malignancies. "